Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug Class
Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious optimism around a class of immunotherapy drugs that has suffered a series of setbacks.
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
Teos Therapeutics (NASDAQ:ITOS) announced Saturday that its experimental cancer doublet therapy developed with GSK (NYSE:GSK) outperformed the British drugmaker’s FDA-approved anti-PD-1 therapy dostarlimab,
TIGIT drug from iTeos shrinks lung tumors in trial
Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.
Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising response rates in patients with a type of lung cancer.
GSK, iTeos lung cancer therapy outperforms Jemperli in mid-stage trial
GALAXIES Lung-201 evaluates new immunotherapy combinations against single-agent immunotherapies such as Merck’s (MRK) Keytruda and
Jemperli
as a first-line option in patients with PD-L1 high non ...
5d
ESMO 2024: TIGIT race tightens with first look at GSK/iTeos’s TIGIT in NSCLC
The published belrestotug/dostarlimab data is still too immature to prove the combination’s capability to disrupt the NSCLC ...
Hosted on MSN
1mon
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial ...
With this approval,
Jemperli
is now indicated earlier in treatment, in combination with chemotherapy, for patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Jemperli
has ...
BioSpace
4d
GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC
High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...
FierceBiotech
6d
UPDATED: iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors
After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...
pharmaphorum
5d
ESMO: GSK, iTeos bring some optimism back to TIGIT
The results of the GALAXIES Lung-02 study reported at the ESMO congress in Barcelona showed that the drug – added to GSK's PD ...
BioSpace
13h
ADCs, Bispecifics and Radiopharma Take Center Stage at ESMO24
The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
GSK
iTeos
TIGIT
GlaxoSmithKline
Feedback